Dr. Bora Lim, MD - University of Texas MD anderson cancer center - Assistant Professor

Dr. Bora Lim

MD

University of Texas MD anderson cancer center

Assistant Professor

Houston, TEXAS | United States

Main Specialties: Oncology

Additional Specialties: Breast Medical Oncology

Dr. Bora Lim, MD - University of Texas MD anderson cancer center - Assistant Professor

Dr. Bora Lim

MD

Introduction

Primary Affiliation: University of Texas MD anderson cancer center - Houston, TEXAS , United States

Specialties:

Additional Specialties:

Research Interests:

Publications

16Publications

643Reads

-Profile Views

125PubMed Central Citations

Current challenges of metastatic breast cancer.

Cancer Metastasis Rev 2016 12;35(4):495-514

Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10555-016-9636-yDOI Listing
December 2016
19 Reads
3 Citations
7.234 Impact Factor

Current and Emerging Systemic Therapy in Gastro-Esophageal Cancer "The Old and New Therapy for Metastatic Disease, The Role of Adjuvant and Neoadjuvant Therapy for Localized Disease".

Curr Clin Pharmacol 2015 ;10(4):267-78

Penn State Hershey Cancer Institute, Penn State Hershey Medical Center, 500 University Dr, CH46, Hershey, PA 17036, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1574884710666151020100329DOI Listing
August 2016
44 Reads
1 Citation

Targeting TRAIL in the treatment of cancer: new developments.

Expert Opin Ther Targets 2015 25;19(9):1171-85. Epub 2015 May 25.

The University of Texas MD Anderson Cancer Center, Department of Cancer Medicine, Breast Medical Oncology , Houston, TX 77030 , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14728222.2015.1049838DOI Listing
April 2016
14 Reads
24 Citations
5.140 Impact Factor

The Actual Role of Receptors as Cancer Markers, Biochemical and Clinical Aspects: Receptors in Breast Cancer.

Adv Exp Med Biol 2015 ;867:327-37

Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Unit 1354, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-94-017-7215-0_20DOI Listing
March 2016
9 Reads
1 Citation

A multiplexed marker-based algorithm for diagnosis of carcinoma of unknown primary using circulating tumor cells.

Oncotarget 2016 Jan;7(4):3662-76

Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Division of Hematology-Oncology, Penn State Hershey Cancer Institute, Hershey, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.6657DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826160PMC
January 2016
22 Reads
6 Citations
6.360 Impact Factor

Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer.

J Cancer 2015 28;6(12):1306-19. Epub 2015 Oct 28.

2. Department of Bioinformatics and Computational Biology - Unit 1410, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/jca.13266DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643087PMC
December 2015
27 Reads
4 Citations
2.640 Impact Factor

Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?

Oncotarget 2015 May;6(15):12890-908

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4536987PMC
http://dx.doi.org/10.18632/oncotarget.3849DOI Listing
May 2015
52 Reads
23 Citations
6.360 Impact Factor

Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10.

Cancer Res 2015 Apr 13;75(8):1668-74. Epub 2015 Feb 13.

Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Department of Medicine (Hematology/Oncology), Penn State Hershey Cancer Institute, Penn State College of Medicine, Hershey, Pennsylvania.

View Article

Download full-text PDF

Source
http://cancerres.aacrjournals.org/content/early/2015/02/13/0
Web Search
http://cancerres.aacrjournals.org/content/75/8/1668.full.pdf
Web Search
http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.
Publisher Site
http://dx.doi.org/10.1158/0008-5472.CAN-14-2356DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4541796PMC
April 2015
20 Reads
14 Citations
9.330 Impact Factor

A Combinatory Strategy for Detection of Live CTCs Using Microfiltration and a New Telomerase-Selective Adenovirus.

Mol Cancer Ther 2015 Mar 14;14(3):835-43. Epub 2015 Jan 14.

Department of C&M Physiology, Penn State College of Medicine, Hershey, Pennsylvania. Department of Pharmaceutical Sciences, College of Pharmacy, Washington State University, Spokane, Washington.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-14-0693DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4456279PMC
March 2015
40 Reads
2 Citations
5.683 Impact Factor

Correlations between molecular subtypes and pathologic response patterns of breast cancers after neoadjuvant chemotherapy.

Ann Surg Oncol 2015 Feb 6;22(2):392-400. Epub 2014 Sep 6.

Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-014-4054-2DOI Listing
February 2015
58 Reads
2 Citations
3.930 Impact Factor

Current treatment of early breast cancer: adjuvant and neoadjuvant therapy.

F1000Res 2014 19;3:198. Epub 2014 Aug 19.

Department of Hematology/Oncology, Penn State College of Medicine, Penn State Hershey Cancer Institute, Penn State Hershey Medical Center, Hershey, PA, 17033, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12688/f1000research.4340.1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224200PMC
November 2014
27 Reads
4 Citations

Two histopathologically different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer.

Breast Cancer Res Treat 2014 Jun 13;145(3):615-23. Epub 2014 May 13.

Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, South Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-014-2983-xDOI Listing
June 2014
49 Reads
8 Citations
3.940 Impact Factor

FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer.

Cancer Biol Ther 2013 Aug 13;14(8):711-9. Epub 2013 Jun 13.

Hematology/Oncology Division, Penn State Hershey Cancer Institute, Penn State Hershey Medical Center, Hershey, PA USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cbt.25310DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3841210PMC
August 2013
26 Reads
1 Citation
3.072 Impact Factor

Update on clinical trials: genetic targets in breast cancer.

Adv Exp Med Biol 2013 ;779:35-54

Penn State University Milton S. Hershey Medical Center, Hershey, PA 17033, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4614-6176-0_2DOI Listing
April 2013
9 Reads
3 Citations

Top co-authors

Hee Jin Lee
Hee Jin Lee

University of Ulsan College of Medicine

3
Joshua E Allen
Joshua E Allen

Laboratory of Translational Oncology and Experimental Cancer Therapeutics

3
Varun V Prabhu
Varun V Prabhu

Penn State Hershey Cancer Institute

3
David T Dicker
David T Dicker

University of Pennsylvania School of Medicine

3
Mala K Talekar
Mala K Talekar

The Children's Hospital of Philadelphia

2
Si-Yang Zheng
Si-Yang Zheng

University Park

2